Key Highlights
- Progressive epilepsy: Starts in childhood and deteriorates over time.
- Multifaceted seizures: Myoclonic, tonic‑clonic and focal seizures commonly occur.
- Genetic origin: Mutations in EPM2A or EPM2B (also called EPM28) disrupt glycogen handling.
- No cure yet: Treatment focuses on symptom control and supportive care.
- Prognosis: Average life span is approximately ten years after onset.
Detailed Insights
Lafora disease manifests predominantly between the ages of eight and nineteen. It is characterized by involuntary muscle jerks—myoclonic seizures—that frequently precede more severe tonic‑clonic seizures. The underlying cause is the abnormal accumulation of glycogen inclusions, referred to as Lafora bodies, within neurons. These inclusions result from dysfunction of the laforin or malin proteins encoded by the EPM2A and EPM2B genes. The progressive degeneration of neural tissue leads to worsening motor, cognitive and speech deficits, eventually requiring continuous care. Diagnosis relies on a combination of neuro‑imaging, electroencephalography and skin biopsy, with definitive confirmation by genetic testing. Management is palliative: antiepileptic drugs, physiotherapy and occupational therapy aim to maintain quality of life, but mortality remains high due to status epilepticus and severe motor loss.
Key Concepts
- Lafora Disease – A rare, autosomal recessive epilepsy that progressively impairs motor and cognitive function.
- Myoclonus – Sudden, brief muscle jerks that are a hallmark seizure type in this condition.
- Glycogen – A glucose polymer stored in cells; its abnormal accumulation causes Lafora bodies.
- Seizure Types – Includes myoclonic, tonic‑clonic, absence, atonic and focal seizures.
- Genetic Testing – Sequencing of EPM2A/EPM2B genes to confirm pathogenic mutations.